![](/img/cover-not-exists.png)
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer
Abramson, Vandana G., Oliveira, Mafalda, Cervantes, Andrés, Wildiers, Hans, Patel, Manish R., Bauer, Todd M., Bedard, Philippe L., Becerra, Carlos, Richey, Stephen, Wei, Michael C., Reyner, Eric, BondLanguage:
english
Journal:
Breast Cancer Research and Treatment
DOI:
10.1007/s10549-019-05360-3
Date:
July, 2019
File:
PDF, 922 KB
english, 2019